Twenty-four-hour urine: elevated levels of glucose tetrasaccharide. Genetic study: carrier heterozygosity mutations c.2173 C> T (p.R725W) and c.2316 G> A (p.W772X).
The treatment was based on four aspects: (a) enzyme replacement therapy (alglucosidase alfa); (b) specifi c diet; (c) physical therapy; and (d) early respiratory rehabilitation, 1 session a day during 14 weeks. In order to: (a) facilitate bronchial drainage; (b) assist effective coughing; (c) encourage diaphragmatic and intercostal muscles; and (d) incentive breathing. After 6 months of treatment, complete motor recovery, weight gain, and muscle mass were achieved. The tracheal cannula was removed, spirometry parameters were normalized (FVC 4.98 l, l FEV1 3.8 FEV1/FVC 85.39.). For a few months he used BiPAP at night, now retired.
CONCLUSIONS
Respiratory failure is a serious threat to these patients. Specifi c treatment with alglucosidase alfa has been shown to modify the natural history, preventing muscle weakness and death from respiratory failure. 1 Pulmonary rehabilitation aims to prevent and resolve respiratory complications of diaphragmatic and intercostal muscle involvement and is associated with mechanical ventilation. 1 The improvement of spirometric parameters suggests that respiratory rehabilitation increases respiratory muscle strength, even in severe weakness. 2 Aerobic exercise helps improve motor function. 3 There are few reports in the literature of cases in which the enzyme therapy and respiratory therapy improve respiratory parameters to the point of being able to leave the intermittent or continuous mechanical ventilation (BiPAP ® ). *Correspondence to: Cecilia Garrino Fernández, University Hospital Puerta del Mar, 11009, Cádiz, Spain. E-mail: ceciliagarrino @gmail.com.
